T4DM: Testosterone Cut Progression to Type 2 Diabetes — With a Catch

T4DM randomized 1,007 Australian men with impaired glucose tolerance or newly diagnosed type 2 diabetes — all of them enrolled in a community lifestyle programme — to two years of injectable testosterone undecanoate or placebo. At two years, 21% of the placebo group met the diabetes threshold on oral glucose tolerance testing versus 12% of the testosterone group: relative risk 0.59, 95% CI 0.43 to 0.80, P = .0007.[1]

It is the strongest evidence that testosterone does something metabolically real. It is also the trial that most clearly shows what that intervention costs.

What makes the design unusual

Nearly every man in T4DM was already doing the thing that works. Both arms were enrolled in a lifestyle programme — so the trial did not ask "does testosterone beat doing nothing?", it asked whether testosterone adds anything on top of diet and exercise.

That is a much harder test, and a much more useful one.

The other notable choice: participants had low testosterone without pathological hypogonadism. Serum testosterone at or below 14.0 nmol/L, but no diagnosed disease of the testes or pituitary. This is the functional-hypogonadism population — men whose levels are low largely because of body weight and metabolic state — which is its own distinct question.

What it did

• Design: randomized, double-blind, placebo-controlled, 2-year, phase 3b trial across six Australian tertiary centres.
• Enrolment: of 19,022 men pre-screened, 1,007 (5%) randomized — 503 placebo, 504 testosterone.
• Eligibility: men 50–74, waist circumference 95 cm or more, serum testosterone 14.0 nmol/L or lower without pathological hypogonadism, and impaired glucose tolerance (2-hour OGTT glucose 7.8–11.0 mmol/L) or newly diagnosed type 2 diabetes with 2-hour glucose no higher than 15.0 mmol/L.
• Intervention: intramuscular testosterone undecanoate 1000 mg or placebo at baseline, 6 weeks, then every 3 months for 2 years.
• Primary outcomes at 2 years: type 2 diabetes (2-hour OGTT glucose ≥ 11.1 mmol/L) and mean change from baseline in 2-hour glucose.
• Recruitment window: February 2013 to February 2017.

Note the screening ratio. Nineteen thousand men were assessed to enrol a thousand — this is a narrowly defined population, not men in general.

What it found

Diabetes at 2 years: 87 of 413 (21%) on placebo versus 55 of 443 (12%) on testosterone. Relative risk 0.59 (95% CI, 0.43–0.80), P = .0007.[1]

Mean change in 2-hour glucose: −0.95 mmol/L on placebo versus −1.70 mmol/L on testosterone. Mean difference −0.75 mmol/L (95% CI, −1.10 to −0.40), P < .0001.[1]

Both arms improved — the lifestyle programme was working. Testosterone roughly doubled the glucose improvement on top of it.

One further detail matters for how the result is generalised: the treatment effect was independent of baseline serum testosterone. Men nearer the top of the eligible range benefited as much as men nearer the bottom, which complicates the intuition that this is simply correcting a deficiency.

The cost side, stated plainly

Haematocrit above 54%: triggered in 106 of 491 (22%) on testosterone versus 6 of 484 (1%) on placebo.[1]

That is a twenty-fold difference, and the authors flag it in their own interpretation: increases in haematocrit might be treatment limiting.

A PSA safety trigger — a rise of 0.75 μg/mL or more — occurred in 109 of 480 (23%) on testosterone versus 87 of 468 (19%) on placebo, a much smaller gap.

Prespecified serious adverse events occurred in 55 of 504 (10.9%) on testosterone versus 37 of 503 (7.4%) on placebo. There were two deaths in each group.

The haematocrit signal is the reason this trial does not read as a straightforward endorsement. It is the same physiology described in the most common side effect of testosterone therapy, showing up here at a rate that would demand active monitoring in one man in five.

What the authors concluded, and did not

Their interpretation: testosterone treatment for two years reduced the proportion of participants with type 2 diabetes beyond the effects of a lifestyle programme; increases in haematocrit might be treatment limiting; and longer-term durability, safety, and cardiovascular effects remain to be further investigated.

Three limits follow from the trial's own design. It ran two years — nothing here speaks to whether the effect persists after stopping. The endpoint is a glucose threshold on an OGTT, not a clinical outcome like heart attack, kidney disease or amputation. And testosterone is not approved anywhere as a diabetes prevention therapy; T4DM is evidence about a mechanism, not a licensed indication.

Related reading on the metabolic side: does TRT fix obesity and the bidirectional trap.

Bottom line

T4DM is the best randomized evidence that testosterone improves glucose handling beyond diet and exercise in overweight men with low-normal testosterone and impaired glucose tolerance — cutting the proportion crossing the diabetes threshold from 21% to 12% over two years. In the same trial, more than a fifth of treated men hit a haematocrit safety trigger. Both halves belong in any account of it.

References

1 source

1. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45. doi:10.1016/S2213-8587(20)30367-3 · PMID 33338415